Abpro Holdings Inc. is a biotechnology company specializing in the development of next-generation antibody therapeutics. Based in Woburn, Massachusetts and established in 2004, the company focuses on creating targeted treatments for a variety of diseases, with a particular emphasis on oncology and immunology. Abpro Holdings is known for its proprietary DiversImmune platform, which is designed to enhance the discovery and development of antibody therapies addressing complex disease targets. The company’s portfolio includes product candidates such as ABP-102 for breast and gastric cancers, ABP-110 for liver cancer, and ABP-105 for gastric cancer treatment. Additionally, Abpro is advancing ABP-201, aimed at treating vascular diseases of the eye, including diabetic macular edema. Through these initiatives, Abpro Holdings seeks to address unmet medical needs in cancer and ocular diseases, positioning itself as an innovator in therapeutic antibody research. The company’s efforts contribute to the broader pharmaceutical and biotech sectors by pushing the boundaries of biologic drug development and targeting challenging clinical indications.